20 0 1981 1985 18 0 1986 1990

卵巢癌：好發年齡 20. 0 1981 -1985 18. 0 1986 -1990 1991 -1995 1996 -2000 16. 0 每十萬人口發生率 2001 -2005 14. 0 12. 0 10. 0 8. 0 6. 0 4. 0 2. 0 0. 0 4 0 - 9 5 - 4 -1 10 9 -1 15 4 -2 20 9 -2 25 4 -3 30 9 -3 35 4 -4 40 9 -4 45 4 -5 50 9 -5 55 -6 60 4 -6 65 9 年齡（歲） 台灣女性卵巢，輸卵管及寬韌帶癌年齡別發生率，依發生年代分，1981 -2005年 -7 70 4 -7 75 9 -8 80 4 + 85

上皮性卵巢癌的預防 Ø 對於有上皮性卵巢癌或乳癌家族史的人，若 經評估檢驗發現確有基因上的風險 (genetically defined risk)，則建議進 行目標性篩檢(targeted screening programs)，加強卵巢與腹膜之監測： 1. 每半年做含彩色都卜勒的陰道超音波 2. 測血中CA 125 值 3. 骨盆腔內診 NCCN (National Comprehensive Cancer Network) Practice Guidelines in Genetic /Familial High-Risk Assessment, version 1. 2002. Standards, Options and Recommendations. Clinical practice guidelines for cancer care from the French National Federation of Cancer (FNCLCC). Ovarian cancer. Bri J Cancer 2001; 84(Suppl 2): 18 -23.

上皮性卵巢癌的病理分類 p p p Serous carcinoma (50~60%) Mucinous carcinoma (20~30%) Endometrioid carcinoma (10~15%) Clear cell carcinoma (5~10%) Transitional cell carcinoma (1~2%) Undifferentiated

Ovarian Yolk Sac Tumor

Ovarian Yolk Sac Tumor

Granulosa Cell Tumor 顆粒細胞瘤

Sertoli-Leydig Cell Tumor 史脫力雷迪格細胞瘤

Ovarian Cancer FIGO Staging

卵巢癌分期 FIGO Stage I

FIGO Stage I

FIGO Stage II

FIGO Stage II

FIGO Stage II

FIGO Stage III

FIGO Stage III

FIGO Stage IV

FIGO Stage IV

th 卵巢癌： 7 FIGO Staging AJCC T N M Stage Ia G 123 Ia 0 0 Ib G 123 Ib 0 0 Ic G 123 Ic 0 0 Stage IIa G 123 IIa 0 0 IIb G 123 IIb 0 0 IIc G 123 IIc 0 0 Stage IIIa G 123 IIIa 0 0 IIIb G 123 IIIb 0 0 IIIc G 123 IIIc 0 0 Any 1 Stage IV G 123　 Note: Liver capsule metastasis T 3/Stage III; liver parenchymal metastasis M 1/Stage IV. Pleural effusion must have positive cytology for M 1/Stage IV.

Thank You for Your Attention !